For injectable formulations, this can be complex because manufacturers must prove their products work identically to the original subcutaneous semaglutide formulations
doi: 10.4049/jimmunol.167.8.4686 55 TamamuraHFujisawaMHiramatsuKMizumotoMNakashimaHYamamotoNet al
& dErrico, G
Most patients are discharged within two to three days if there are no major post-surgical complications
In terms of safety and tolerability, the adverse events were primarily mild to moderate gastrointestinal reactions, with no reports of severe hypoglycemia or death.161 In summary, dual and triple agonists related to GLP-1 represent significant advances in the field of diabetes treatment,167,168 demonstrating the future trend of enhancing therapeutic effects by targeting multiple biomarkers.136,169,170 With the accumulation of more clinical data and the development of new drugs, these treatment options are expected to provide more effective and comprehensive treatment choices for diabetes patients.161,167 GLP-1 .124,125,126 , , .43 , .127,128 GLP-1R .124,129 GLP-1 GIP .130 , ( Mounjaro) GLP-1 GIPR .124 GLP-1 .131,132,133 , GLP-1 .121,134 GIP , GLP-1 .125,130 2022, 2 FDA .135,136 , .135 , T2DM .136,137,138 , .139,140,141 , .141 , .141,142 3 , , 7 77 .143 2 , .143 , 2
